MedPath

Rintatolimod

Generic Name
Rintatolimod
Drug Type
Biotech
CAS Number
38640-92-5
Unique Ingredient Identifier
94325AJ25N
Clinical Trials
Related News

AIM ImmunoTech Advances Ampligen Study as Potential Avian Flu Vaccine Booster with Promising Cross-Protection

• AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management. • Previous research at University of Alabama-Birmingham demonstrated Ampligen's ability to boost FluMist vaccine response four-fold and induce protection against multiple avian flu strains. • The company is pursuing collaborative grants to support a follow-up clinical study combining Ampligen with AstraZeneca's FluMist nasal vaccine.

AIM ImmunoTech Advances to Phase 2 Trial of Ampligen-Imfinzi Combination for Late-Stage Pancreatic Cancer

• Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment. • The trial, conducted at Erasmus Medical Center in the Netherlands, addresses a critical unmet need in oncology, with pancreatic cancer claiming approximately 50,000 American lives annually. • The combination therapy aims to enhance immune system response through Ampligen's immune reprogramming properties alongside Imfinzi's checkpoint inhibition mechanism.

Ampligen Shows Potential in Treating Fatigue in Post-COVID Conditions, AIM ImmunoTech Announces

• AIM ImmunoTech's AMP-518 study results support Ampligen as a potential therapeutic for moderate-to-severe Post-COVID fatigue. • Patients treated with Ampligen in the AMP-518 trial showed improvement in the Six-Minute Walk Test (6MWT) compared to placebo. • A subset of patients with baseline 6MWT scores under 205 meters experienced a significant mean improvement of 139 meters with Ampligen. • AIM ImmunoTech plans to focus future trials on Ampligen's therapeutic potential for moderate or worse COVID-related fatigue or ME/CFS symptoms.

AIM ImmunoTech Announces Clinical Milestones and Upcoming Studies for Ampligen

• AIM ImmunoTech highlights the continued development of Ampligen (rintatolimod) across multiple clinical programs targeting pancreatic cancer and Long-COVID. • Several key milestones are anticipated in the next 18 months, with trials partially funded by the National Cancer Institute, AstraZeneca, and Merck. • Positive preliminary data were reported from a Phase 1b/2 study of Ampligen and Imfinzi for late-stage pancreatic cancer, and Phase 2 data for post-COVID fatigue. • AIM ImmunoTech received patents for Ampligen in treating endometriosis and post-COVID fatigue, and completed cGMP manufacturing of 9,042 clinical vials.

Novel Immunotherapy Approach Shows Promise in Triple-Negative Breast Cancer

• A phase 1 clinical trial at Roswell Park Comprehensive Cancer Center reveals a promising new treatment for triple-negative breast cancer (TNBC). • The novel regimen achieved a 66% remission rate in early-stage TNBC patients without immune-related adverse events. • The treatment combines chemotherapy drugs with a chemokine modulatory regimen (CKM) to enhance the immune response against tumors. • Further studies are needed to validate these findings in a larger patient population and confirm the efficacy of the CKM therapy.

Rintatolimod and Durvalumab Combination Shows Promise in Late-Stage Pancreatic Cancer

• Preliminary data from the DURIPANC trial indicates that rintatolimod plus durvalumab demonstrates early disease control in late-stage pancreatic cancer. • Two of three patients in the first dose cohort maintained stable disease at 6 months, with ongoing treatment and assessment. • The combination therapy was generally well-tolerated, with no severe adverse effects observed in the first cohort. • Improvements in quality of life were noted, correlating with stable disease, offering hope for patients with limited treatment options.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy